valproic acid has been researched along with Genetic Predisposition in 45 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of this 5-year naturalistic study of patients treated with clozapine was to examine the incidence of treatment-emergent diabetes mellitus in relation to other factors, including weight gain, lipid abnormalities, age, clozapine dose, and treatment with valproate." | 9.09 | Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. ( Cagliero, E; Goff, DC; Gray, C; Hayden, DL; Henderson, DC; Nasrallah, RA; Schoenfeld, DA, 2000) |
| "There is a large inter-individual variation in the efficacy of valproic acid (VPA) against epilepsy." | 7.91 | SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients. ( Chen, X; Li, H; Lin, C; Luo, J; Shi, L; Wen, Z; Zhang, Z; Zhu, M, 2019) |
| "This study was aimed at identifying genetic and non-genetic risk factors for valproic acid (VPA)-induced hyperammonaemia in Chinese paediatric patients with epilepsy." | 7.88 | Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy. ( Li, X; Zhang, T; Zhao, L; Zhu, X, 2018) |
| "Weight gain is the most frequent adverse effect of valproic acid (VPA) treatment, resulting in poor compliance and many endocrine disturbances." | 7.81 | Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid. ( Chen, X; Chen, Z; Hou, X; Huang, M; Li, H; Li, J; Ni, G; Su, Q; Wang, X; Xie, W; Xin, S; Zhou, L; Zhou, Y, 2015) |
| "Valproic acid, which is widely used to treat various types of epilepsy, may cause severe hyperammonemia." | 7.80 | 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy. ( Hayashi, H; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Miyakawa, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Yamamoto, Y; Yazawa, R, 2014) |
| "The goal of this 5-year naturalistic study of patients treated with clozapine was to examine the incidence of treatment-emergent diabetes mellitus in relation to other factors, including weight gain, lipid abnormalities, age, clozapine dose, and treatment with valproate." | 5.09 | Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. ( Cagliero, E; Goff, DC; Gray, C; Hayden, DL; Henderson, DC; Nasrallah, RA; Schoenfeld, DA, 2000) |
| "This study revealed the higher risk of cardiac arrhythmias persists long term in people with epilepsy, especially among those using carbamazepine and valproic acid." | 4.31 | Epilepsy and long-term risk of arrhythmias. ( Cai, J; Feng, Z; Huang, P; Liu, P; Lu, J; Lu, Y; Tang, H; Wang, J; Yang, G; Yang, Y; Yu, Q; Yuan, H, 2023) |
| "There is a large inter-individual variation in the efficacy of valproic acid (VPA) against epilepsy." | 3.91 | SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients. ( Chen, X; Li, H; Lin, C; Luo, J; Shi, L; Wen, Z; Zhang, Z; Zhu, M, 2019) |
| "This study was aimed at identifying genetic and non-genetic risk factors for valproic acid (VPA)-induced hyperammonaemia in Chinese paediatric patients with epilepsy." | 3.88 | Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy. ( Li, X; Zhang, T; Zhao, L; Zhu, X, 2018) |
| "Weight gain is the most frequent adverse effect of valproic acid (VPA) treatment, resulting in poor compliance and many endocrine disturbances." | 3.81 | Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid. ( Chen, X; Chen, Z; Hou, X; Huang, M; Li, H; Li, J; Ni, G; Su, Q; Wang, X; Xie, W; Xin, S; Zhou, L; Zhou, Y, 2015) |
| "Valproic acid, which is widely used to treat various types of epilepsy, may cause severe hyperammonemia." | 3.80 | 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy. ( Hayashi, H; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Miyakawa, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Yamamoto, Y; Yazawa, R, 2014) |
| "Recent advances in schizophrenia (SZ) research indicate that the telencephalic gamma-aminobutyric acid (GABA)ergic neurotransmission deficit associated with this psychiatric disorder probably is mediated by the hypermethylation of the glutamic acid decarboxylase 67 (GAD(67)), reelin and other GABAergic promoters." | 3.75 | Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. ( Costa, E; Dong, E; Grayson, DR; Guidotti, A; Kundakovic, M; Satta, R, 2009) |
| "Folic acid supplementation reduces the occurrence of neural tube defects (NTDs); however, it is not clear whether it protects against teratogenic effects of antiepileptic drugs." | 3.74 | Plasma vitamin values and antiepileptic therapy: case reports of pregnancy outcomes affected by a neural tube defect. ( Boisson, C; Candito, M; Gaucherand, P; Guéant, JL; Luton, D; Naimi, M; Rudigoz, JC; Van Obberghen, E, 2007) |
| "Individually, childhood epilepsy and migraine are two of the most common conditions seen in pediatric neurology." | 2.50 | Migraine and epilepsy in the pediatric population. ( Kossoff, EH; Oakley, CB, 2014) |
| "To review our clinical experience and determine if there are appropriate signs and symptoms to consider POLG sequencing prior to valproic acid (VPA) dosing in patients with seizures." | 1.36 | POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. ( Bao, X; Koenig, MK; Lee, IC; Naviaux, RK; Saneto, RP; Weng, SW; Wong, LJ, 2010) |
| "This article describes a girl with mental retardation, probably due to a perinatal complication, who had typical absence seizures with characteristic electroencephalographic findings of childhood absence epilepsy, including normal background activity." | 1.35 | Childhood absence epilepsy with clinically apparent genetic and acquired burdens: a diagnostic consideration. ( Wakamoto, H, 2008) |
| "Levetiracetam (LEV) treatment was started in combination with VPA in a patient with typical clinical, histological, and biochemical features of MERRF due to a mutation on the tRNA of Phenilalanine gene." | 1.33 | Antimyoclonic effect of levetiracetam in MERRF syndrome. ( Filosto, M; Galli, R; Mancuso, M; Murri, L; Pizzanelli, C; Siciliano, G, 2006) |
| "Identifying genes for bipolar mood disorders through classic genetics has proven difficult." | 1.32 | Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. ( Geyer, MA; Kuczenski, R; Lohr, JB; Niculescu, AB; Ogden, CA; Paulus, MP; Rich, ME; Schork, NJ, 2004) |
| "Despite the frequency of seizure disorders in the human population, the genetic basis for these defects remains largely unclear." | 1.31 | Anticonvulsant valproate reduces seizure-susceptibility in mutant Drosophila. ( Kuebler, D; Tanouye, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (44.44) | 29.6817 |
| 2010's | 20 (44.44) | 24.3611 |
| 2020's | 5 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, L | 1 |
| Li, H | 3 |
| Zeng, G | 1 |
| Shi, L | 2 |
| Zhu, M | 2 |
| Luo, J | 2 |
| Zhang, Z | 2 |
| Wang, J | 2 |
| Huang, P | 1 |
| Yu, Q | 1 |
| Lu, J | 1 |
| Liu, P | 1 |
| Yang, Y | 1 |
| Feng, Z | 1 |
| Cai, J | 1 |
| Yang, G | 1 |
| Yuan, H | 1 |
| Tang, H | 1 |
| Lu, Y | 1 |
| Gesche, J | 1 |
| Hjalgrim, H | 1 |
| Rubboli, G | 1 |
| Beier, CP | 1 |
| Devries, S | 1 |
| Mulder, M | 1 |
| Charron, JG | 1 |
| Prokop, JW | 1 |
| Mark, PR | 1 |
| Tang, Y | 1 |
| Liu, Y | 1 |
| Tong, L | 1 |
| Feng, S | 1 |
| Du, D | 1 |
| Chen, F | 1 |
| Zhu, X | 1 |
| Li, X | 1 |
| Zhang, T | 2 |
| Zhao, L | 3 |
| Kim, KH | 1 |
| Song, JS | 1 |
| Park, CW | 1 |
| Ki, CS | 1 |
| Heo, K | 1 |
| Wang, ZJ | 1 |
| Chen, J | 1 |
| Chen, HL | 1 |
| Zhang, LY | 1 |
| Xu, D | 1 |
| Jiang, WT | 1 |
| Ma, L | 1 |
| Pan, Y | 1 |
| Sun, M | 1 |
| Shen, H | 1 |
| Guo, Y | 1 |
| Wen, Z | 1 |
| Chen, X | 2 |
| Lin, C | 1 |
| Chukwu, J | 1 |
| Delanty, N | 1 |
| Webb, D | 1 |
| Cavalleri, GL | 1 |
| Oakley, CB | 1 |
| Kossoff, EH | 1 |
| Inoue, K | 1 |
| Suzuki, E | 1 |
| Takahashi, T | 1 |
| Yamamoto, Y | 1 |
| Yazawa, R | 1 |
| Takahashi, Y | 1 |
| Imai, K | 1 |
| Miyakawa, K | 1 |
| Inoue, Y | 1 |
| Tsuji, D | 1 |
| Hayashi, H | 1 |
| Itoh, K | 1 |
| SanGiovanni, JP | 1 |
| Rosen, R | 1 |
| Kaushal, S | 1 |
| Wang, X | 1 |
| Zhou, Y | 1 |
| Ni, G | 1 |
| Su, Q | 1 |
| Chen, Z | 2 |
| Li, J | 1 |
| Hou, X | 1 |
| Xie, W | 1 |
| Xin, S | 1 |
| Zhou, L | 1 |
| Huang, M | 1 |
| Villegas-Martínez, I | 1 |
| de-Miguel-Elízaga, I | 1 |
| Carrasco-Torres, R | 1 |
| Marras, C | 1 |
| Canteras-Jordana, M | 1 |
| Yedra-Guzmán, MJ | 1 |
| Martínez-Villanueva, M | 1 |
| Tortosa-Conesa, D | 1 |
| Martín-Fernández, J | 1 |
| Chen, PS | 2 |
| Chang, HH | 1 |
| Huang, CC | 1 |
| Lee, CC | 1 |
| Lee, SY | 2 |
| Chen, SL | 2 |
| Huang, SY | 2 |
| Yang, YK | 2 |
| Lu, RB | 2 |
| Chang, TT | 1 |
| Chang, YH | 1 |
| Chu, CH | 1 |
| Chen, SH | 1 |
| Tzeng, NS | 1 |
| Wang, LJ | 1 |
| Wang, TY | 1 |
| Li, CL | 1 |
| Chung, YL | 1 |
| Hsieh, TH | 1 |
| Lee, IH | 1 |
| Chen, KC | 1 |
| Hong, JS | 1 |
| Jiang, HZ | 1 |
| Wang, SY | 1 |
| Yin, X | 1 |
| Jiang, HQ | 1 |
| Wang, XD | 1 |
| Wang, TH | 1 |
| Qi, Y | 1 |
| Yang, YQ | 1 |
| Wang, Y | 1 |
| Zhang, CT | 1 |
| Feng, HL | 1 |
| Zhao, M | 1 |
| Li, G | 1 |
| Qiu, F | 1 |
| Sun, Y | 1 |
| Miklowitz, DJ | 1 |
| Chang, KD | 1 |
| Guidotti, A | 1 |
| Dong, E | 1 |
| Kundakovic, M | 1 |
| Satta, R | 1 |
| Grayson, DR | 1 |
| Costa, E | 1 |
| Saneto, RP | 1 |
| Lee, IC | 1 |
| Koenig, MK | 1 |
| Bao, X | 1 |
| Weng, SW | 1 |
| Naviaux, RK | 1 |
| Wong, LJ | 1 |
| Senn, SM | 1 |
| Kantor, S | 1 |
| Poulton, IJ | 1 |
| Morris, MJ | 1 |
| Sims, NA | 1 |
| O'Brien, TJ | 1 |
| Wark, JD | 1 |
| Bezinover, D | 1 |
| Postula, M | 1 |
| Donahue, K | 1 |
| Bentzen, B | 1 |
| McInerney, J | 1 |
| Janicki, PK | 1 |
| Chen, DT | 1 |
| Jiang, X | 1 |
| Akula, N | 1 |
| Shugart, YY | 1 |
| Wendland, JR | 1 |
| Steele, CJ | 1 |
| Kassem, L | 1 |
| Park, JH | 1 |
| Chatterjee, N | 1 |
| Jamain, S | 1 |
| Cheng, A | 1 |
| Leboyer, M | 1 |
| Muglia, P | 1 |
| Schulze, TG | 1 |
| Cichon, S | 1 |
| Nöthen, MM | 1 |
| Rietschel, M | 1 |
| McMahon, FJ | 1 |
| Farmer, A | 1 |
| McGuffin, P | 1 |
| Craig, I | 1 |
| Lewis, C | 1 |
| Hosang, G | 1 |
| Cohen-Woods, S | 1 |
| Vincent, JB | 1 |
| Kennedy, JL | 1 |
| Strauss, J | 1 |
| Kaplan, PW | 1 |
| Schlattman, DK | 1 |
| Polifka, JE | 1 |
| Friedman, JM | 1 |
| Malm, H | 1 |
| Kajantie, E | 1 |
| Kivirikko, S | 1 |
| Kääriäinen, H | 1 |
| Peippo, M | 1 |
| Somer, M | 1 |
| Kuebler, D | 1 |
| Tanouye, M | 1 |
| Lundberg, YW | 1 |
| Cabrera, RM | 1 |
| Greer, KA | 1 |
| Zhao, J | 1 |
| Garg, R | 1 |
| Finnell, RH | 4 |
| Ogden, CA | 1 |
| Rich, ME | 1 |
| Schork, NJ | 1 |
| Paulus, MP | 1 |
| Geyer, MA | 1 |
| Lohr, JB | 1 |
| Kuczenski, R | 1 |
| Niculescu, AB | 1 |
| Jacquet, H | 1 |
| Demily, C | 1 |
| Houy, E | 1 |
| Hecketsweiler, B | 1 |
| Bou, J | 1 |
| Raux, G | 1 |
| Lerond, J | 1 |
| Allio, G | 1 |
| Haouzir, S | 1 |
| Tillaux, A | 1 |
| Bellegou, C | 1 |
| Fouldrin, G | 1 |
| Delamillieure, P | 1 |
| Ménard, JF | 1 |
| Dollfus, S | 1 |
| D'Amato, T | 1 |
| Petit, M | 1 |
| Thibaut, F | 1 |
| Frébourg, T | 1 |
| Campion, D | 1 |
| Mancuso, M | 1 |
| Galli, R | 1 |
| Pizzanelli, C | 1 |
| Filosto, M | 1 |
| Siciliano, G | 1 |
| Murri, L | 1 |
| Galimberti, CA | 1 |
| Diegoli, M | 1 |
| Sartori, I | 1 |
| Uggetti, C | 1 |
| Brega, A | 1 |
| Tartara, A | 1 |
| Arbustini, E | 1 |
| Candito, M | 1 |
| Naimi, M | 1 |
| Boisson, C | 1 |
| Rudigoz, JC | 1 |
| Gaucherand, P | 1 |
| Guéant, JL | 1 |
| Luton, D | 1 |
| Van Obberghen, E | 1 |
| Findling, RL | 1 |
| Frazier, TW | 1 |
| Youngstrom, EA | 1 |
| McNamara, NK | 1 |
| Stansbrey, RJ | 1 |
| Gracious, BL | 1 |
| Reed, MD | 1 |
| Demeter, CA | 1 |
| Calabrese, JR | 1 |
| Wakamoto, H | 1 |
| Craig, JC | 1 |
| Bennett, GD | 2 |
| Miranda, RC | 1 |
| Mackler, SA | 1 |
| Henderson, DC | 1 |
| Cagliero, E | 1 |
| Gray, C | 1 |
| Nasrallah, RA | 1 |
| Hayden, DL | 1 |
| Schoenfeld, DA | 1 |
| Goff, DC | 1 |
| Gelineau-van Waes, J | 1 |
| Barber, RC | 1 |
| Wlodarczyk, B | 1 |
| Shaw, GM | 1 |
| Lammer, EJ | 1 |
| Piedrahita, JA | 1 |
| Eberwine, JH | 1 |
| Duncan, S | 1 |
| Mercho, S | 1 |
| Lopes-Cendes, I | 1 |
| Seni, MH | 1 |
| Benjamin, A | 1 |
| Dubeau, F | 1 |
| Andermann, F | 1 |
| Andermann, E | 1 |
| Walker, UA | 1 |
| Venhoff, N | 1 |
| Heckmann, JG | 1 |
| Tomandl, B | 1 |
| Erbguth, F | 1 |
| Neidhardt, B | 1 |
| Zingsem, H | 1 |
| Neundörfer, B | 1 |
| Waes, JG | 1 |
| Eudy, JD | 1 |
| Rosenquist, TH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Family-Focused Therapy as Early Treatment for Youth at Risk for Bipolar Disorder[NCT00943085] | 52 participants (Anticipated) | Interventional | 2007-04-30 | Completed | |||
| Early Intervention for Youth at Risk for Bipolar Disorder[NCT01483391] | 150 participants (Anticipated) | Interventional | 2011-10-06 | Completed | |||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis[NCT00337350] | Phase 4 | 20 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033] | Phase 4 | 38 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
Acute insulin response to glucose (AIRG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. AIRG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. AIRG measures the acute(0-10 min) beta cell response to a glucose load calculated by the areas under the curve higher than basal insulin values. The AIRG was assessed as the incremental area under the curve (calculated by the trapezoid rule) from 0 to 10 min of the FSIVGTT. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | Units/mL per 10 minutes (Mean) |
|---|---|
| Rosiglitazone | -151 |
| Placebo | 19 |
Insulin Sensitivity (IS) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in IS between Baseline and week 8. SI was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SI represents the increase in net fractional glucose clearance rate per unit change in serum insulin concentration after the intravenous glucose load (microUnits/mL). (NCT00337350)
Timeframe: baseline, week 8
| Intervention | microUnits/mL (Mean) |
|---|---|
| Rosiglitazone | 3.2 |
| Placebo | 0.4 |
Glucose utilization (SG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. SG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SG represents the net fractional glucose clearance rate because of the increase in glucose independent of any increase in circulating insulin concentrations above baseline. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Rosiglitazone | .002 |
| Placebo | -0.01 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.52 |
| Placebo | 0.03 |
A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Aripiprazole | 0.003 |
| Placebo | -0.005 |
A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Aripiprazole | 0.6 |
| Placebo | 0.65 |
A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -15.3 |
| Placebo | 5.6 |
(NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -5.9 |
| Placebo | -7.3 |
A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg (Mean) |
|---|---|
| Aripiprazole | -1.5 |
| Placebo | 0.3 |
6 reviews available for valproic acid and Genetic Predisposition
| Article | Year |
|---|---|
Association between SCN1A polymorphism rs3812718 and valproic acid resistance in epilepsy children: a case-control study and meta-analysis.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Resistance; Epilepsy; Female; Genetic Ass | 2018 |
Weight change, genetics and antiepileptic drugs.
Topics: Animals; Anticonvulsants; Epilepsy; gamma-Aminobutyric Acid; Genetic Predisposition to Disease; Huma | 2014 |
Migraine and epilepsy in the pediatric population.
Topics: Anticonvulsants; Child; Child, Preschool; Comorbidity; Diagnosis, Differential; Diet, Ketogenic; Epi | 2014 |
Prevention of bipolar disorder in at-risk children: theoretical assumptions and empirical foundations.
Topics: Adolescent; Adult; Affect; Amygdala; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; | 2008 |
Prevention of bipolar disorder in at-risk children: theoretical assumptions and empirical foundations.
Topics: Adolescent; Adult; Affect; Amygdala; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; | 2008 |
Prevention of bipolar disorder in at-risk children: theoretical assumptions and empirical foundations.
Topics: Adolescent; Adult; Affect; Amygdala; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; | 2008 |
Prevention of bipolar disorder in at-risk children: theoretical assumptions and empirical foundations.
Topics: Adolescent; Adult; Affect; Amygdala; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; | 2008 |
Medical genetics: 1. Clinical teratology in the age of genomics.
Topics: Adult; Alcohol Drinking; Anticonvulsants; Environmental Exposure; Epilepsy; Female; Genetic Counseli | 2002 |
Molecular basis of environmentally induced birth defects.
Topics: Abnormalities, Drug-Induced; Animals; Embryonic and Fetal Development; Female; Gene Expression Regul | 2002 |
4 trials available for valproic acid and Genetic Predisposition
| Article | Year |
|---|---|
The DRD3 Ser9Gly Polymorphism Predicted Metabolic Change in Drug-Naive Patients With Bipolar II Disorder.
Topics: Bipolar Disorder; DNA; Dose-Response Relationship, Drug; Double-Blind Method; Female; GABA Agents; G | 2016 |
Hyperprolinemia is a risk factor for schizoaffective disorder.
Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Case-Control Studies; Chromosomes, | 2005 |
Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Double-Blind Method; Female; Genetic Predispo | 2007 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
Topics: Adult; Age Factors; Antipsychotic Agents; Body Mass Index; Body Weight; Cholesterol; Clozapine; Diab | 2000 |
35 other studies available for valproic acid and Genetic Predisposition
| Article | Year |
|---|---|
Correlation of GSTP1 rs1695 and CAT rs769217 with elevated AST induced by valproate sodium in Chinese children with epilepsy.
Topics: Adolescent; Anticonvulsants; Aspartate Aminotransferases; Catalase; Chemical and Drug Induced Liver | 2021 |
Epilepsy and long-term risk of arrhythmias.
Topics: Atrial Fibrillation; Carbamazepine; Epilepsy; Genetic Predisposition to Disease; Humans; Valproic Ac | 2023 |
The clinical spectrum of familial and sporadic idiopathic generalized epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy, Generalized; Female; Genetic Predisposition to Disease | 2020 |
SLC6A1 G443D associated with developmental delay and epilepsy.
Topics: Child, Preschool; Developmental Disabilities; Epilepsy; Female; GABA Plasma Membrane Transport Prote | 2020 |
Identification of a
Topics: Animals; Autistic Disorder; beta-Arrestin 2; Disease Models, Animal; Exome Sequencing; Female; Gene | 2020 |
Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
Topics: Age Factors; Ammonia; Anticonvulsants; Aspartate Aminotransferases; Chemical and Drug Induced Liver | 2018 |
First Molecular Diagnosis of a Patient with Unverricht-Lundborg Disease in Korea.
Topics: Adult; Anticonvulsants; Blotting, Southern; Cystatin B; Female; Genetic Predisposition to Disease; H | 2018 |
Catalase C-262T Polymorphism Is a Risk Factor for Valproic Acid-Induced Abnormal Liver Function in Chinese Patients With Epilepsy.
Topics: Adolescent; Anticonvulsants; Asian People; Catalase; Chemical and Drug Induced Liver Injury; Child; | 2019 |
SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients.
Topics: Adolescent; Adult; Anticonvulsants; Asian People; Child; Child, Preschool; Epilepsy; Female; Genetic | 2019 |
4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.
Topics: Alleles; Amino-Acid N-Acetyltransferase; Ammonia; Anticonvulsants; Asian People; Biomarkers, Pharmac | 2014 |
Application and interpretation of genome-wide association (GWA) studies for informing pharmacogenomic research - examples from the field of age-related macular degeneration.
Topics: GABA Agents; Gene Regulatory Networks; Genetic Predisposition to Disease; Genome-Wide Association St | 2014 |
Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid.
Topics: Adolescent; Adult; AMP-Activated Protein Kinases; Anticonvulsants; Body Weight; Chromatography, High | 2015 |
The COL1A1 SP1 polymorphism is associated with lower bone mineral density in patients treated with valproic acid.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Bone Density; Collagen Type I; Collagen Type I, alp | 2016 |
A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate.
Topics: Adult; Antimanic Agents; Biomarkers; Bipolar Disorder; Body Mass Index; Case-Control Studies; Dyslip | 2017 |
Downregulation of Homer1b/c in SOD1 G93A Models of ALS: A Novel Mechanism of Neuroprotective Effect of Lithium and Valproic Acid.
Topics: Amyotrophic Lateral Sclerosis; Animals; Apoptosis; Cell Line; Genetic Predisposition to Disease; Hom | 2016 |
Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
Topics: Adolescent; Adult; Alleles; Anticonvulsants; Biotransformation; Chemical and Drug Induced Liver Inju | 2017 |
Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling.
Topics: Animals; Antipsychotic Agents; Cell Adhesion Molecules, Neuronal; Chromatin Assembly and Disassembly | 2009 |
POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Diffuse Cerebral Sclerosis of Schilder; DNA Mu | 2010 |
Adverse effects of valproate on bone: defining a model to investigate the pathophysiology.
Topics: Animals; Bone Density; Bone Diseases; Disease Models, Animal; Female; Genetic Predisposition to Dise | 2010 |
Perioperative exacerbation of valproic acid-associated hyperammonemia: a clinical and genetic analysis.
Topics: Adult; Carbamoyl-Phosphate Synthase (Ammonia); Carbamoyl-Phosphate Synthase I Deficiency Disease; Ch | 2011 |
Genome-wide association study meta-analysis of European and Asian-ancestry samples identifies three novel loci associated with bipolar disorder.
Topics: Ankyrins; Antidepressive Agents; Asian People; Bipolar Disorder; Cell Line, Transformed; Cytokines; | 2013 |
Comparison of triphasic waves and epileptic discharges in one patient with genetic epilepsy.
Topics: Anticonvulsants; Brain; Brain Mapping; Brain Waves; Diagnosis, Differential; Electroencephalography; | 2012 |
Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Child; Child, Preschool; Developmental Disabil | 2002 |
Anticonvulsant valproate reduces seizure-susceptibility in mutant Drosophila.
Topics: Action Potentials; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Dru | 2002 |
Mapping a chromosomal locus for valproic acid-induced exencephaly in mice.
Topics: Animals; Anticonvulsants; Chromosome Mapping; Crosses, Genetic; Female; Genetic Predisposition to Di | 2004 |
Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach.
Topics: Animals; Antimanic Agents; Bayes Theorem; Bipolar Disorder; Brain; Central Nervous System Stimulants | 2004 |
Antimyoclonic effect of levetiracetam in MERRF syndrome.
Topics: Activities of Daily Living; Anticonvulsants; Atrophy; Brain; Drug Therapy, Combination; Female; Gene | 2006 |
Brain pseudoatrophy and mental regression on valproate and a mitochondrial DNA mutation.
Topics: Adult; Aged; Anticonvulsants; Atrophy; Brain; Child; Cognition Disorders; Developmental Disabilities | 2006 |
Plasma vitamin values and antiepileptic therapy: case reports of pregnancy outcomes affected by a neural tube defect.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Folic Acid; Genetic Predisposition to Disease; Homocystein | 2007 |
Childhood absence epilepsy with clinically apparent genetic and acquired burdens: a diagnostic consideration.
Topics: Action Potentials; Anticonvulsants; Birth Injuries; Brain; Causality; Child; Child, Preschool; Comor | 2008 |
Ribonucleotide reductase subunit R1: a gene conferring sensitivity to valproic acid-induced neural tube defects in mice.
Topics: Animals; Anticonvulsants; Embryonic and Fetal Development; Female; Gene Expression Regulation, Devel | 2000 |
Genetic basis of susceptibility to environmentally induced neural tube defects.
Topics: Animals; Carrier Proteins; Cell Cycle; Disease Models, Animal; DNA Fingerprinting; Embryonic and Fet | 2000 |
Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Genetic Predisposition to Disease; Gravidity; Humans; Neur | 2001 |
Multiple mitochondrial DNA deletions and lactic acidosis in an HIV-infected patient under antiretroviral therapy.
Topics: Acidosis, Lactic; Anti-HIV Agents; Cell Line; DNA, Mitochondrial; Drug Therapy, Combination; Enzyme | 2001 |
Cerebral vein thrombosis and prothrombin gene (G20210A) mutation.
Topics: Adult; Age Factors; Aged; Blood Coagulation Disorders; Cerebral Veins; Female; Genetic Predispositio | 2001 |